Abeona Therapeutics Inc.
corporate_fare Company Profile
Abeona Therapeutics Inc. (NASDAQ:ABEO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ABEO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ABEO spans 10-Q, 8-K, SCHEDULE 13D, 144.
Recent high-impact activity:
- Abeona Q3: ZEVASKYN Revenue $13.5M, Net Loss Narrows to $4.8M, $134.9M Cash
- Abeona Buys Phase 3 EoE Drug, Raises $30M at $3.75 a Share
- Abeona Q3: ZEVASKYN Revenue $13.5M, Net Loss Narrows to $4.8M, Cash $134.9M
- Abeona Posts $13.5M in Q3 Revenue, Topping Q2's $11.4M
- Abeona Buys Phase 3-Ready ABO-801 for $20M Stock, Raises $30M PIPE at $3.75
Financial Snapshot
Short Interest & Short Volume
21.67 days to coverFINRA reported short interest of 16,879,896 shares in ABEO as of the October 30, 2026 settlement, a 1.9% decrease from the prior period — about 21.7 days to cover at its recent average daily volume. On November 20, 2026, 19.2% of ABEO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ABEO, detected from its recent SEC filings.
Resale Shelf Covers 12.49M Shares · Placement Priced at $3.75
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →